ClinicalTrials.gg
CompletedNCT01355289Updated Feb 22, 2018Results posted

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

A Phase 2 interventional study of Avatrombopag and Placebo in Thrombocytopenia, sponsored by Eisai Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-22.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.

Enrollment
10th of 23
65 · median 50
Started
2011
the only one that year
Phase 2
10 of 23
3 open now
Registered
2nd of 23
by date
Lead sponsor
5 of 23
Eisai Inc.

Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 10th largest by enrollment, is the only one that started in 2011, is one of 10 in phase 2, and was the 2nd registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing avatrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.

Read the detailed description

This study had three phases: Prerandomization (Screening), Randomization (Core Study), and Open-Label Extension (OLE). The Randomization Phase included Treatment Periods A1 and A2 and a Follow-up Period (for those participants not continuing into the OLE phase). The OLE Phase included Treatment Periods B1, B2, and B3 (depending on when a participant entered the OLE), and a Follow-up Period. Participants may have been followed for sustained viral response, if appropriate. In the Core Study (randomization phase) participants were randomized (in a 1:1:1:1 ratio) to receive one of four treatments (placebo or avatrombopag [10mg, 20mg, and 30mg] for up to 21 days. Participants who successfully completed Treatment Period A1, (platelet count >=100x10\^9/L) initiated antiviral treatment with pegylated interferon (PEG-IFN) alpha-2a and progressed to Treatment Period A2. Participants with a platelet count >=150x10\^9/L initiated antiviral treatment and progressed into Treatment Period B2, study drug was interrupted then eventually restarted at 10 mg daily once their platelet counts returned to acceptable levels. Those who were not considered successful after 21 days in Treatment Phase A1 were withdrawn from the Core Study (Part A) and were eligible to enter the OLE at Treatment Period B1. Participants who chose to not enter the OLE entered into the Follow-up Phase. At the end of Treatment Period A2, eligible participants could enter the OLE at Treatment Period B3. In the OLE Phase, participants entering into Open-label Treatment Period B1 began once-daily treatment with avatrombopag at a dose of 20 mg without titration for up to 21 days. Once the participant's platelet counts were sufficient, they entered Treatment Period B2. Participant's eligible to enter into Treatment Period B2 received avatrombopag and antiviral treatment for 13 weeks. Participants who successfully completed Treatment Period A2 or B2 could continue on antiviral treatment for up to a maximum of 48 weeks (including the 13 weeks in Treatment Periods A2 or B2) and open-label avatrombopag, at the investigator's discretion. In Treatment Period B3, the dose of avatrombopag was allowed to be titrated up or down in accordance with the participant's platelet count response, within the range of a minimum of 5 mg and a maximum of 50 mg. In the Follow-up Period, participants were seen at either a single 30-day follow-up visit or followed for the full 30 days after the last dose of avatrombopag.

03

Conditions studied

  • Thrombocytopenia

Browse trials for

Keywords

  • Chronic Hepatitis C related
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Males or females greater than or equal to 18 years of age
  2. Women of must agree to use a highly effective method of for at least one menstrual cycle prior to starting study drug, throughout the entire study period, and for 30 days after the last dose of study drug
  3. Subjects with chronic -related thrombocytopenia (defined as a count greater than or equal to 20x10\^9/L to 70x10\^9/L) who require antiviral treatment
  4. Chronic HCV infection (defined as the presence of anti-HCV antibodies and detectable serum HCV RNA levels)
  5. Model for End-stage Liver disease score greater than or equal to 24
  6. Adequate renal function as evidenced by a calculated greater than or equal to 50 mL/minute per the Cockcroft and Gault formula
  7. greater than or equal to 3 months

Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from participation in the study:

  1. Any history of arterial or venous thrombosis, including partial or complete thrombosis (e.g., stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism), thrombosis (partial or complete) in the main portal vein and portal vein branches, and thrombosis of any part of the splenic-mesenteric system
  2. Any evidence of current portal vein thrombosis (PVT) as detected by Doppler sonography and portal vein flow rate less than 15 cm/second at Screening or within 30 days prior to Screening (revised per Amendment 02)
  3. Any known family history of hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency)
  4. Evidence of myocardial infarction in the last 6 months or uncompensated congestive heart failure ( Class III or IV)
  5. Co-infection with (HIV) or or acute hepatitis C
  6. Any prohibited concomitant medications or therapy that cannot be discontinued by Visit 1, e.g., subjects currently receiving interferon who cannot undergo a 4-week prior to Screening, or subjects who receive blood products that affect platelet count within 1 week prior to Screening (revised per Amendment 02)
  7. Weekly alcohol intake greater than 21 units (168 g) [male] and greater than 14 units (112 g) [female]
  8. Any known medical condition, other than chronic liver disease, that can lead to thrombocytopenia
  9. History of hepatocellular carcinoma, liver cancer, or liver transplantation (revised per Amendment 01) (revised per Amendment 02)
  10. History of idiopathic thrombocytopenic Purpura (ITP)
  11. History of myelodysplastic syndrome
  12. History of pernicious anemia or subjects with vitamin B12 deficiency (defined as less than the lower limit of normal [LLN]) who have not had pernicious anemia excluded as a cause (Added per Amendment 02)
  13. Evidence of disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that, in the opinion of the investigator, could affect the subject's safety or study conduct
  14. Subjects with a history of suicide attempts
  15. Subjects with a history of hospitalization for depression within the past 5 years
  16. Subjects with any current severe or poorly controlled psychiatric or seizure disorder
  17. Current use of recreational drugs
  18. Subjects who have participated in another study within 30 days prior to Visit 1
  19. Subjects with , intolerance, or allergy to E5501 or any anti-HCV therapies or their ingredients
  20. Any past or current (revised per Amendment 01) medical condition that, in the opinion of the investigator, would compromise the subject's ability to safely complete the study
  21. Scheduled for surgery during the projected course of the study
  22. Subjects who have any medical conditions or diseases that would contraindicate treatment with anti-HCV therapy (added per Amendment 01)
  23. Subjects who are currently treated with proton pump inhibitors (PPIs) or H2-antagonist therapy but have not been receiving a stable dose for at least 6 weeks prior to randomization or have not completed these therapies more than 2 weeks prior to randomization (added per Amendment 01)
  24. Fasting gastrin-17 blood levels exceeding 1.5 times the (ULN) at Screening (including subjects on PPIs or H2 antagonists) (revised per Amendment 02)
  25. Subjects with a history of gastric atrophy (added per Amendment 02)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Core Study)

    Placebo, will be administered orally, once daily for up to 21 days.

    Drug: Placebo

  • Active comparator
    Avatrombopag 10 mg (Core Study)

    Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.

    Drug: Avatrombopag

  • Active comparator
    Avatrombopag 20 mg (Core Study)

    Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.

    Drug: Avatrombopag · Drug: Pegylated interferon (PEG-IFN) · Drug: Telaprevir · Drug: Ribavirin

  • Active comparator
    Avatrombopag 30 mg (Core Study)

    Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.

    Drug: Avatrombopag

  • Experimental
    Avatrombopag (Open-Label Extension)

    Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.

    Drug: Avatrombopag · Drug: Pegylated interferon (PEG-IFN) · Drug: Telaprevir · Drug: Ribavirin

Interventions

  • Also known as: E5501, Avatrombopag maleate

  • DrugPlacebo
  • Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.

  • Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

    Also known as: Incivek, Incivo

  • Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor

    Also known as: Virazole, Rebetol, Copegus, Ribasphere, Moderiba dose pack, Moderiba

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study

    A responder was defined as a participant having a platelet count of greater than or equal to 100x10\^9/L by Day 21 starting from an average baseline platelet count of greater than 20 x 10\^9/L to less than or equal to 70 x 10\^9/L.

    Time frame: Baseline to Day 21

Secondary outcomes

  1. Change From Baseline of Local Platelet Count by Visit During Treatment Period A1 of Core Study

    Missing platelet counts were imputed using last observation carried forward (LOCF) approach for subjects who achieved platelet response at prior visits.

    Time frame: Day 7 and Day 14

  2. Number of Participants Who Achieved Platelet Count Greater Than 30 X 10^9/L From Baseline to Day 21 During Treatment Period A1 of Core Study

    Blood draws were taken to monitor platelet counts.

    Time frame: Baseline to Day 21

  3. Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study

    Blood draws were taken to monitor platelet counts during the first 21 days of study treatment. When a platelet count of greater than or equal to 100 X 10\^9/L was attained, antiviral treatment was initiated.

    Time frame: Baseline to Day 21

07

Results

Posted Feb 22, 2018

Participant flow

Core Study
Participant flow — Core Study
MilestonePlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)Avatrombopag (Open Label Extension)
Started171618140
Completed161618120
Not completed10020
Withdrew: Adverse event, non-fatal10000
Withdrew: Inadequate therapeutic effect00010
Withdrew: Other00010
Open Label Extension
Participant flow — Open Label Extension
MilestonePlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)Avatrombopag (Open Label Extension)
Started000062
Completed000028
Not completed000034
Withdrew: Adverse event, non-fatal00001
Withdrew: Lost to follow-up00001
Withdrew: Inadequate therapeutic effect000029
Withdrew: Other00003

Outcome measures

SecondaryChange From Baseline of Local Platelet Count by Visit During Treatment Period A1 of Core Study

Missing platelet counts were imputed using last observation carried forward (LOCF) approach for subjects who achieved platelet response at prior visits.

Time frame:
Day 7 and Day 14
Reported as:
Mean · cells x 10^9/L
Change From Baseline of Local Platelet Count by Visit During Treatment Period A1 of Core Study
cells x 10^9/LPlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)
Day 7-0.1 ± 7.1519.8 ± 17.5926.5 ± 22.0630.9 ± 37.65
Day 14-0.2 ± 13.7929.2 ± 18.3257.2 ± 31.3955.4 ± 37.47
SecondaryNumber of Participants Who Achieved Platelet Count Greater Than 30 X 10^9/L From Baseline to Day 21 During Treatment Period A1 of Core Study

Blood draws were taken to monitor platelet counts.

Time frame:
Baseline to Day 21
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Platelet Count Greater Than 30 X 10^9/L From Baseline to Day 21 During Treatment Period A1 of Core Study
ParticipantsPlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)
Yes191611
No16723
PrimaryNumber of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study

A responder was defined as a participant having a platelet count of greater than or equal to 100x10\^9/L by Day 21 starting from an average baseline platelet count of greater than 20 x 10\^9/L to less than or equal to 70 x 10\^9/L.

Time frame:
Baseline to Day 21
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study
ParticipantsPlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)
Yes16129
No161065
Statistical analysis
  • Placebo (Core Study) vs Avatrombopag 10 mg (Core Study) · Cochran-Mantel-Haenszel · p = 0.0236 · Difference in % of responders: 31.62 · 95% CI 5.39 to 57.84
  • Placebo (Core Study) vs Avatrombopag 20 mg (Core Study) · Cochran-Mantel-Haenszel · p = 0.0003 · Difference in % of responders: 60.78 · 95% CI 36.30 to 85.27
  • Placebo (Core Study) vs Avatrombopag 30 mg (Core Study) · Cochran-Mantel-Haenszel · p = 0.0003 · Difference in % of responders: 58.4 · 95% CI 30.92 to 85.88
SecondaryNumber of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study

Blood draws were taken to monitor platelet counts during the first 21 days of study treatment. When a platelet count of greater than or equal to 100 X 10\^9/L was attained, antiviral treatment was initiated.

Time frame:
Baseline to Day 21
Reported as:
Count of participants · Participants
Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study
ParticipantsPlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)
Yes16139
No161055

Adverse events

Collected over For each participant, treatment emergent adverse events were collected from the first day of administration of study drug up to 30 days after the last dose of study drug or up to approximately 2.5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Core Study)—0/17 (0%)6/17 (35.3%)
Avatrombopag 10 mg (Core Study)—1/16 (6.3%)11/16 (68.8%)
Avatrombopag 20 mg (Core Study)—0/18 (0%)12/18 (66.7%)
Avatrombopag 30 mg (Core Study)—1/14 (7.1%)11/14 (78.6%)
Avatrombopag (Open Label Extension)—13/64 (20.3%)55/64 (85.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)Avatrombopag (Open Label Extension)
ParaesthesiaNervous system disorders0/170/160/181/141/64
ThrombocytopeniaBlood and lymphatic system disorders0/171/160/180/142/64
AnaemiaBlood and lymphatic system disorders0/170/160/180/142/64
NeutropeniaBlood and lymphatic system disorders0/170/160/180/142/64
LeukopeniaBlood and lymphatic system disorders0/170/160/180/141/64
PancytopeniaBlood and lymphatic system disorders0/170/160/180/141/64
Abdominal painGastrointestinal disorders0/170/160/180/141/64
Hepatic massHepatobiliary disorders0/170/160/180/141/64
GastroenteritisInfections and infestations0/170/160/180/141/64
Urinary tract infectionInfections and infestations0/170/160/180/141/64
Most frequent other events
Showing 10 of 80
Most frequent other events
EventPlacebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)Avatrombopag (Open Label Extension)
AnaemiaBlood and lymphatic system disorders0/172/162/181/1421/64
NeutropeniaBlood and lymphatic system disorders0/172/164/182/1420/64
NauseaGastrointestinal disorders0/173/164/182/1420/64
FatigueGeneral disorders0/171/163/182/1416/64
PruritusSkin and subcutaneous tissue disorders0/174/160/182/1415/64
Influenza like illnessGeneral disorders2/171/164/183/1411/64
LeukopeniaBlood and lymphatic system disorders0/171/163/181/1414/64
InsomniaPsychiatric disorders1/171/160/183/1413/64
CoughRespiratory, thoracic and mediastinal disorders0/170/162/183/149/64
ChillsGeneral disorders1/173/163/181/1413/64

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)Total
Mean50.2 ± 7.9655.3 ± 8.0654.9 ± 7.3853.6 ± 7.2653.5 ± 7.78
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Core Study)Avatrombopag 10 mg (Core Study)Avatrombopag 20 mg (Core Study)Avatrombopag 30 mg (Core Study)Total
Female345517
Male141213948
08

Study locations

2 sites
  • Health Care Consultants
    Los Angeles, California, United States
  • Metropolitan Research
    Fairfax, Virginia 22031, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Feb 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 4 years after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2011
First posted
May 18, 2011
Start
Nov 2011
Primary completionActual
Feb 2014
CompletionActual
May 2014
Results delay requested
Jun 29, 2015
Results first posted
Feb 22, 2018
Last update
Feb 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01355289
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
May 18, 2011
Start date
Nov 2011
Primary completion
Feb 2014
Completion
May 2014
Results posted
Feb 22, 2018
Last update
Feb 22, 2018

Study contacts

Alireza Manhuchehri
study director · Eisai Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion